Benitec Biopharma (BNTC) EPS (Weighted Average and Diluted) (2021 - 2025)
Benitec Biopharma (BNTC) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.42 as the latest value for Q2 2025.
- Quarterly EPS (Weighted Average and Diluted) fell 281.82% to -$0.42 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$1.04 through Jun 2025, up 82.75% year-over-year, with the annual reading at -$1.05 for FY2025, 13.93% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.42 in Q2 2025 for Benitec Biopharma, down from -$0.24 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.11 in Q2 2024 to a low of -$36.27 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$3.68 across 5 years, with a median of -$0.62 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 3940.32% in 2022 and later soared 95.85% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.59 in 2021, then crashed by 466.1% to -$3.34 in 2022, then rose by 20.96% to -$2.64 in 2023, then soared by 92.42% to -$0.2 in 2024, then crashed by 110.0% to -$0.42 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for BNTC at -$0.42 in Q2 2025, -$0.24 in Q1 2025, and -$0.2 in Q4 2024.